Search

Search Constraints

You searched for: Author/Creator Gumuscu, Burak

Search Results

1. KEYNOTE-630: Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC). Issue 1 (January 2023)

2. KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC). Issue 1 (January 2023)

3. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. Issue 21 (20th July 2022)

4. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Issue 10212 (23rd November 2019)

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Issue 10212 (23rd November 2019)

6. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Issue 4 (1st February 2023)